News BioNTech to buy rival mRNA firm CureVac for $1.25bn BioNTech has agreed to buy another specialist in mRNA medicines, fellow German biotech CureVac, for around $1.25 billion.
News FDA clears Nuvation's first product Ibtrozi, for lung cancer Nuvation is set to launch its first commercial product after the FDA approved its ROS1 inhibitor Ibtrozi as a treatment for ROS1-positive lung cancer.
News BMS' radiopharma unit builds with $1.35bn Philochem deal Bristol Myers Squibb has expanded its push into radiopharma by licensing a prostate cancer therapy developed by Philochem for $350m upfront.
News AZ claims EU approval for new Calquence regimens in CLL AstraZeneca has secured a key approval for its BTK inhibitor Calquence in Europe, currently facing a strong challenge from BeOne's rival Brukinsa.
Patients Delivering the right behavioural ingredients for the moment,... Lirio's Dr Amy Bucher discusses the risks of the declining trust in healthcare institutions from a behavioural science perspective.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
